M1FG
MRNS

Mach-1 Financial Group’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Mach-1 Financial Group’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-43,828
Closed -$476K – 236
2023
Q4 		$476K Sell
43,828
-24,375
-36% -$183K 0.18% 119
2023
Q3 		$549K Buy
+68,203
New +$567K 0.23% 95

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Mach-1 Financial Group's MRNS Position: Q1 2024 in Review

Mach-1 Financial Group sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2024, closing a stake of 43,828 shares — an estimated $476K sold.

Mach-1 Financial Group first reported a position in MRNS in Q3 2023 and held it in 2 quarters. The position peaked at $549K in Q3 2023. 112 funds tracked by Wall St. Rank hold MRNS as of Q1 2024.

  • Mach-1 Financial Group reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2024 after selling out during the quarter.
  • Mach-1 Financial Group sold 43,828 Marinus Pharmaceuticals, Inc shares in Q1 2024, an estimated $476K.
  • Mach-1 Financial Group first reported a position in Marinus Pharmaceuticals, Inc in Q3 2023 and held it in 2 quarters.
  • Mach-1 Financial Group's Marinus Pharmaceuticals, Inc position peaked at $549K in Q3 2023.
  • 112 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2024.

Based on Mach-1 Financial Group's 13F filing for Q1 2024, filed 10 May 2024.